US Executive Director, Early Assets · US Medical

Tue, 28 Apr 2026 15:09:00 GMT
Engineering

US Medical · Wilmington, Delaware, United States of America · $331,874 to $497,810 · hybrid

Are you ready to turn ideas into life-changing medicines? At AstraZeneca, scientific innovation drives everything we do to address unmet patient needs. In this role, reporting directly to the US Executive Director Early Assets, the US Executive Director, Early Assets will lead the development of bold US medical strategies for our early pipeline, provide scientific input to cross-functional teams, and build an influential external network across US disease areas where AstraZeneca has pipeline programs.

This is a chance to develop, design, and influence across a complex matrix so that US perspectives are embedded in global development plans and future launches. Want to be at the point where early science meets real-world impact?

Lead the US medical strategy for early pipeline assets, ensuring alignment with portfolio priorities, disease area strategy, and long-term business objectives.

Act as the internal US medical authority for emerging assets, providing authoritative mentorship on scientific, clinical, and real-world considerations across cardiovascular, metabolism, and related therapeutic areas.

Partner closely with global medical and R&D teams to shape robust translational and early clinical development plans, integrating US medical insights, health system realities, and real-world data opportunities.

Influence study builds and development strategies by collaborating with Clinical, Global Commercial, and Medical teams on endpoints, comparators, inclusion/exclusion criteria, and real-world evidence plans that enable future US access, labeling, and promotion.

Craft clear and compelling scientific narratives that differentiate early assets, support value propositions, and underpin impactful launch and lifecycle strategies.

Drive evidence generation plans across the product lifecycle, including clinical trials and real-world evidence initiatives that support practice change and guideline evolution in the US.

Build and coordinate comprehensive external engagement strategies with US authorities, professional societies, policy influencers, and patient groups to inform development plans and accelerate adoption of innovation.

Play a key role in medical advisory boards and scientific exchanges, ensuring high-quality insight generation that shapes both global and US strategies.

Build and nurture a strong external network across all relevant programs and disease areas, positioning AstraZeneca as a trusted scientific partner in obesity/weight management, cardiovascular disease, metabolism, and adjacent fields.

Champion cross-functional collaboration within a complex matrix environment, connecting stakeholders across Medical, R&D, Commercial, Market Access, HEOR, and Policy to drive coordinated decision-making.

Identify and act on opportunities to accelerate early asset development, de-risk key decisions, and prepare the US market for first-in-class or best-in-class launches.